批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2005/07/07 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
STANDARD
|
|
|
>>>补充申请<<<
审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2018/05/18 |
SUPPL-16(补充) |
Approval |
Labeling-Patient Package Insert |
STANDARD
|
|
|
2015/09/03 |
SUPPL-14(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2015/07/09 |
SUPPL-13(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
2013/11/08 |
SUPPL-12(补充) |
Approval |
Labeling-Container/Carton Labels |
UNKNOWN
|
|
|
2013/10/31 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2013/10/03 |
SUPPL-11(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2009/03/26 |
SUPPL-6(补充) |
Approval |
Labeling-Package Insert |
N/A
|
|
|
2008/03/14 |
SUPPL-5(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
与本品治疗等效的药品
>>>活性成分:DAPSONE; 剂型/给药途径:GEL;TOPICAL; 规格:5%; 治疗等效代码:AB<<<
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021794 |
001 |
NDA |
ACZONE |
DAPSONE |
GEL;TOPICAL |
5% |
Prescription |
Yes |
Yes |
AB |
2005/07/07
|
ABBVIE |
209506 |
001 |
ANDA |
DAPSONE |
DAPSONE |
GEL;TOPICAL |
5% |
Prescription |
No |
No |
AB |
2017/10/16
|
TARO |
210178 |
001 |
ANDA |
DAPSONE |
DAPSONE |
GEL;TOPICAL |
5% |
Prescription |
No |
No |
AB |
2022/03/31
|
COSETTE |
213907 |
001 |
ANDA |
DAPSONE |
DAPSONE |
GEL;TOPICAL |
5% |
Prescription |
No |
No |
AB |
2023/06/06
|
TRUPHARMA |
212383 |
001 |
ANDA |
DAPSONE |
DAPSONE |
GEL;TOPICAL |
5% |
Prescription |
No |
No |
AB |
2023/10/13
|
ENCUBE |
209890 |
001 |
ANDA |
DAPSONE |
DAPSONE |
GEL;TOPICAL |
5% |
Prescription |
No |
No |
AB |
2023/10/19
|
AMNEAL |
215087 |
001 |
ANDA |
DAPSONE |
DAPSONE |
GEL;TOPICAL |
5% |
Discontinued |
No |
No |
AB |
2023/10/31
|
PADAGIS ISRAEL |
218457 |
001 |
ANDA |
DAPSONE |
DAPSONE |
GEL;TOPICAL |
5% |
Prescription |
No |
No |
AB |
2025/04/04
|
AUROBINDO PHARMA LTD |